New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
08:05 EDTADHDAlcobra announces enrollment of first patient in Phase IIb clinical trial of MDX
Alcobra announced that the first patient has been enrolled in a Phase IIb Fragile X study of MDX. The FDA granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome in December 2013. The Phase IIb Fragile X trial is a multi-center, randomized, placebo-controlled study and is being conducted in 11 clinical sites, primarily in the U.S. It is designed to investigate MDX for 6 weeks compared with placebo in 60 adolescent and adult subjects with Fragile X Syndrome.
News For ADHD From The Last 14 Days
Check below for free stories on ADHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
16:24 EDTADHDAlcobra announces completion of all patient visits in phase 3 MDX trial
Subscribe for More Information
September 12, 2014
11:03 EDTADHDOptions with increasing implied volatility
Options with increasing implied volatility: ADHD VNET AVNO RAX VALE NLY EWZ BBBY SYY GGP
September 10, 2014
11:23 EDTADHDOptions with increasing implied volatility
Subscribe for More Information
September 9, 2014
12:08 EDTADHDOptions with increasing implied volatility
Subscribe for More Information
September 8, 2014
10:17 EDTADHDAlcobra October volatility elevated into Phase III trial data
Alcobra September call option implied volatility is at 170, October is a t 289, December is at 203; compared to its 13-week average of 187 according to Track Data, suggesting large October price movement into Phase III trial data of MDX in adult ADHD subjects.
09:33 EDTADHDAlcobra Phase III data could be major stock mover, says FBR Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use